Katzung Basic & Clinical Pharmacology.pdf

(105673 KB) Pobierz
ir
h
ta
9
9
-
te
i
n
U
V
d
G
R
S C H E D U L E
SCHEDULE I
O F
C O N T R O L L E D
D R U G S
1
(All nonresearch use illegal under federal law.)
Flunitrazepam (Rohypnol)
Narcotics:
Heroin and many nonmarketed synthetic narcotics
Hallucinogens:
LSD
MDA, STP, DMT, DET, mescaline, peyote, bufotenine, ibogaine,
psilocybin, phencyclidine (PCP; veterinary drug only)
Marijuana
Methaqualone
Depressants:
Schedule II barbiturates in mixtures with noncontrolled drugs or in
suppository dosage form
Barbiturates (butabarbital [Butisol], butalbital [Fiorinal])
Ketamine (Ketalar)
Cannabinoids:
Dronabinol (Marinol)
Anabolic Steroids:
Fluoxymesterone (Androxy), Methyltestosterone
(Android, Testred, Methitest), Nandrolone decanoate (Deca-
Durabolin) Non US, Nandrolone phenpropionate (Durabolin) Non
US, Oxandrolone (Oxandrin), Oxymetholone (Androl-50), Stanozolol
(Winstrol), Testolactone (Teslac), Testosterone and its esters
SCHEDULE II
(No telephone prescriptions, no refills.)
2
Opioids:
Opium
Opium alkaloids and derived phenanthrene alkaloids: codeine,
morphine (Avinza, Kadian, MSContin, Roxanol), hydrocodone and
hydrocodone combinations (Zohydro ER, Hycodan, Vicodin,
Lortab), hydromorphone (Dilaudid), oxymorphone (Exalgo),
oxycodone (dihydroxycodeinone, a component of Oxycontin,
Percodan, Percocet, Roxicodone, Tylox)
Designated synthetic drugs: meperidine (Demerol), methadone,
levorphanol (Levo-Dromoran), fentanyl (Duragesic, Actiq,
Fentora), alfentanil (Alfenta), sufentanil (Sufenta), remifentanil
(Ultiva), tapentadol (Nycynta)
Stimulants:
Coca leaves and cocaine
Amphetamines: Amphetamine complex (Biphetamine),
Amphetamine salts (Adderall), Dextroamphetamine (Dexedrine,
Procentra), Lisdexamfetamine (Vyvanse), Methamphetamine
(Desoxyn), Methylphenidate (Ritalin, Concerta, Methylin,
Daytrana, Medadate), Above in mixtures with other controlled or
uncontrolled drugs
Cannabinoids:
Nabilone (Cesamet)
Depressants:
Amobarbital (Amytal)
Pentobarbital (Nembutal)
Secobarbital (Seconal)
SCHEDULE IV
(Prescription must be rewritten after 6 months or five refills; differs from
Schedule III in penalties for illegal possession.)
Opioids:
Butorphanol (Stadol)
Difenoxin 1 mg
+
atropine 25 mcg (Motofen)
Pentazocine (Talwin)
Stimulants:
Armodafinil (Nuvigil)
Diethylpropion (Tenuate) not in US
Modafinil (Provigil)
Phentermine (Ionamin, Adipex-P)
Depressants:
Benzodiazepines: Alprazolam (Xanax), Chlordiazepoxide (Librium),
Clonazepam (Klonopin), Clorazepate (Tranxene), Diazepam
(Valium), Estazolam (ProSom), Flurazepam (Dalmane), Halazepam
(Paxipam), Lorazepam (Ativan), Midazolam (Versed), Oxazepam
(Serax), Prazepam (Centrax), Quazepam (Doral), Temazepam
(Restoril) Triazolam (Halcion)
Chloral hydrate (Somnote)
Eszopiclone (Lunesta)
Lacosamide (Vimpat)
Meprobamate (Equanil, Miltown, etc)
Methobarbital (Mebaral)
Methohexital (Brevital)
Paraldehyde
Phenobarbital
Zaleplon (Sonata)
Zolpidem (Ambien)
SCHEDULE III
(Prescription must be rewritten after 6 months or five refills.)
Opioids:
Buprenorphine (Buprenex, Subutex)
Mixture of above Buprenorphine and Naloxone (Suboxone)
The following opioids in combination with one or more active
non-opioid ingredients, provided the amount does not exceed that
shown:
Codeine and dihydrocodeine: not to exceed 1800 mg/dL or 90 mg/
tablet or other dosage unit
Opium: 500 mg/dL or 25 mg/5 mL or other dosage unit (paregoric)
Stimulants:
Benzphetamine (Didrex)
Phendimetrazine (Bontril)
1
2
SCHEDULE V
(As any other nonopioid prescription drug)
Codeine: 200 mg/100 mL
Difenoxin preparations: 0.5 mg
+
25 mcg atropine
Dihydrocodeine preparations: 10 mg/100 mL
Diphenoxylate (not more than 2.5 mg and not less than 0.025 mg of
atropine per dosage unit, as in Lomotil)
Ethylmorphine preparations: 100 mg/100 mL
Opium preparations: 100 mg/100 mL
Pregabalin (Lyrica)
Pyrovalerone (Centroton, Thymergix)
See http://www.usdoj.gov/dea/pubs/scheduling.html for additional details.
Emergency prescriptions may be telephoned if followed within 7 days by a valid written prescription annotated to indicate that it was previously placed by
telephone.
a LANGE medical book
Basic & Clinical
Pharmacology
Thirteenth Edition
Edited by
Professor Emeritus
Department of Cellular & Molecular Pharmacology
University of California, San Francisco
Associate Editor
Bertram G. Katzung, MD, PhD
Anthony J. Trevor, PhD
Professor Emeritus
Department of Cellular & Molecular Pharmacology
University of California, San Francisco
New York Chicago San Francisco Athens London Madrid
Mexico City Milan New Delhi Singapore Sydney Toronto
Copyright © 2015 by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced
or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher, with the exception that the program listings
may be entered, stored, and executed in a computer system, but they may not be reproduced for publication.
ISBN: 978-0-07-182641-9
MHID: 0-07-182641-6
The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-182505-4,
MHID: 0-07-182505-3.
eBook conversion by codeMantra
Version 1.0
All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only,
and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.
McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a
representative, please visit the Contact Us page at www.mhprofessional.com.
Notice
Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the
publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the
time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved
in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors
or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For
example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information
contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular
importance in connection with new or infrequently used drugs.
TERMS OF USE
This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under
the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works
based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education’s prior consent. You may use the work for your own
noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.
THE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY,
ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED
THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that
the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable
to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for
the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, puni-
tive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of
liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.
Contents
Preface vii
Authors ix
S E C T I O N
I
1
10.
Adrenoceptor Antagonist Drugs
Basic PrinciPles
David robertson, MD, & italo Biaggioni, MD
152
1.
Introduction: The Nature of Drugs & Drug
Development & Regulation
Bertram G. Katzung, MD, PhD
1
S E C T I O N
III
CArDiovASCULAr-rENAL
DrUgS 169
11.
Antihypertensive Agents
neal l. Benowitz, MD
169
2.
Drug Receptors & Pharmacodynamics
Mark von Zastrow, MD, PhD
20
3.
Pharmacokinetics & Pharmacodynamics:
Rational Dosing & the Time Course
of Drug Action
4.
Drug Biotransformation
5.
Pharmacogenomics
12.
Vasodilators & the Treatment
of Angina Pectoris
13.
Drugs Used in Heart Failure
Bertram G. Katzung, MD, PhD
191
nicholas H. G. Holford, MB, chB, FracP
41
Maria almira correia, PhD
56
Bertram G. Katzung, MD, PhD
209
14.
Agents Used in Cardiac Arrhythmias
Joseph r. Hume, PhD, & augustus O.
Grant, MD, PhD
224
Jennifer e. Hibma, PharmD,
& Kathleen M. Giacomini, PhD
74
S E C T I O N
II
87
15.
Diuretic Agents
ramin sam, MD, David Pearce, MD, &
Harlan e. ives, MD, PhD
249
aUTOnOMic DrUGs
6.
Introduction to Autonomic Pharmacology
Bertram G. Katzung, MD, PhD
87
S E C T I O N
IV
7.
Cholinoceptor-Activating &
Cholinesterase-Inhibiting Drugs
achilles J. Pappano, PhD
105
DrUgS WiTH iMPorTANT ACTioNS
oN SMooTH MUSCLE 271
16.
Histamine, Serotonin, & the Ergot Alkaloids
Bertram G. Katzung, MD, PhD
271
8.
Cholinoceptor-Blocking Drugs
achilles J. Pappano, PhD
121
17.
Vasoactive Peptides
ian a. reid, PhD
294
9.
Adrenoceptor Agonists &
Sympathomimetic Drugs
italo Biaggioni, MD, & David robertson, MD
133
18.
The Eicosanoids: Prostaglandins,
Thromboxanes, Leukotrienes, & Related
Compounds
emer M. smyth, PhD, & Garret a.
FitzGerald, MD
313
iii

Plik z chomika:

Inne pliki z tego folderu:

Inne foldery tego chomika:

Zgłoś jeśli naruszono regulamin